http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201817744-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2012-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e65f50862c48d4aaec00394220ac78a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af226973a2cded1df8049b2cdb9fa5d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b012f8252b63b4dd712c030781d8054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ede7adcadd6021cabd2ce1b6249ded3b |
| publicationDate | 2018-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201817744-A |
| titleOfInvention | Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance |
| abstract | The present invention provides: a modified FcRn binding domain with enhanced affinity for Fc neonatal receptor (FcRn) at neutral pH; an antigen-binding molecule comprising the above FcRn binding domain, which has low immunogenicity and high stability And only a few agglutinates; modified antigen-binding molecules that have increased FcRn binding activity at neutral or acidic pH and no increased binding activity to pre-existing anti-drug antibodies at neutral pH; Use for improving the uptake of an antigen into a cell by an antigen-binding molecular medium; use of the above-mentioned antigen molecule for reducing the plasma concentration of a specific antigen; and the above-mentioned modified FcRn-binding domain for increasing a single unit that an antigen pair can bind before its degradation Use of the total number of antigen-binding molecules; use of the aforementioned modified FcRn-binding domains to improve the pharmacokinetics of the antigen-binding molecules; methods for reducing the binding activity to pre-existing anti-drug antibodies; and for the production of the above-mentioned antigens Method of binding molecules. |
| priorityDate | 2011-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 203.